The abstract is read at the publisher; the summary is JClub's.
In advanced solid tumors treated with pembrolizumab, endogenous retroelement transcription—especially Alu and LINE—is upregulated in immunotherapy responders, linked to durable clinical benefit and improved long-term outcomes.
- Why it matters: Endogenous retrotransposable element activity may shape immune responses, but its relationship to checkpoint-inhibitor sensitivity and durable outcomes in patients is not well defined.
- What they did: ERE expression was measured in pre- and on-treatment samples from a pembrolizumab clinical trial, then correlated with interferon-stimulated gene profiles, immune-cell infiltration, and cytolytic activity; two external datasets in melanoma and non-small cell lung cancer were used for validation.
- The result: Responders showed a treatment-associated rise in ERE transcription that correlated with CD8+ T-cell infiltration and cytolytic activity, with a trend toward increased A-to-I RNA editing; external validation confirmed a consistent ERE pattern, supporting ERE transcription as a potential biomarker.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.